This trial is testing if a new drug combo is safe and effective against plasmacytoma.
1 Primary · 0 Secondary · Reporting Duration: At the end of Cycle 6 (each cycle is 28 days)
Experimental Treatment
20 Total Participants · 1 Treatment Group
Primary Treatment: CC-486 · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: